Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 6/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.82 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.82 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.82 |
| ▸ | TSHR | P16473 | 4/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.78 |
| ▸ | LMNA | P02545 | 5/20 | 0.78 |
| ▸ | MEN1 | O00255 | 2/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.78 |
| ▸ | NPSR1 | Q6W5P4 | 7/20 | 0.70 |
| ▸ | GAA | P10253 | 3/20 | 0.61 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4206437 | 0.88 | SMN1; SMN2 (0.78) | HTTSMN1; SMN2POLBADRB2CYP1A2 | |
| SCHEMBL15503864 | 0.88 | ALDH1A1 (1.00) | HTTSMN1; SMN2POLBADRB2CYP1A2 | |
| SCHEMBL6410268 | 0.83 | CYP1A2 (0.87) | HTTSMN1; SMN2POLBADRB2CYP1A2 | |
| SCHEMBL6406142 | 0.80 | CYP1A2 (0.67) | HTTSMN1; SMN2POLBADRB2CYP1A2 | |
| SCHEMBL4215113 | 0.80 | TSHR (0.76) | HTTSMN1; SMN2POLBADRB2CYP1A2 | |
| SCHEMBL6403245 | 0.79 | TSHR (0.82) | HTTSMN1; SMN2POLBADRB2CYP1A2 | |
| SCHEMBL6404140 | 0.76 | TSHR (0.71) | HTTSMN1; SMN2POLBADRB2CYP1A2 | |
| SCHEMBL4200762 | 0.76 | TSHR (0.73) | HTTSMN1; SMN2POLBADRB2CYP1A2 | |
| SCHEMBL4211122 | 0.75 | TSHR (0.62) | HTTSMN1; SMN2POLBADRB2CYP1A2 | |
| SCHEMBL4206640 | 0.74 | HTT (0.59) | HTTSMN1; SMN2POLBADRB2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190240195-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | Board of Regents of the Nevada System of Higher Education, on behalf of the Univ of Nevada, Reno (US) | 2019-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190240195-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | ITGB7, ITGA2B, ITGB1 | HTT 4298/4885SMN1; SMN2 22/4885POLB 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.